Cancer Clinical Trial
Official title:
Antigen-specific Engineered Immune Effector Cells (EIE) Against Gastro-Intestinal (GI) Cancer
The primary objectives are to evaluate the safety and efficacy of infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE).
Gastro-intestinal (GI) cancer is becoming the top-ranked high mortality cancer in recent
years. Every year, approximate 5,300,000 people in China are diagnosed with cancer, of which
about 2,000,000 die each year, and esophagus cancer, gastric cancer and colorectal cancer
account for ~50% of all GI cancer cases. GI cancer causes 500 thousand deaths a year. In
China, nearly 85% of patients with cancer of the digestive tract are in middle to late stage
at diagnosis. Regardless of the treatment, the five year survival rate is only 36%. GI
cancers include cancer in the oral cavity, pharynx, esophagus, stomach, small intestine
(duodenum, jejunum, ileum) and large intestine (cecum, colon, rectum). The main malignant
tumors of the GI tract are esophageal, gastric, colorectal, liver, and pancreatic cancer.
Adoptive immunotherapy based on cytotoxic T lymphocytes reactive with specific antigens has
proven to be effective in many studies. In vitro induction of cancer antigen-specific immune
cells and genetic engineering of target specific immune cells have great potential for cancer
eradication. This study aims to evaluate the safety and efficacy of ex vivo manipulated EIE
cells including chimeric antigen receptor (CAR) modified immune cells in treating cancer. The
primary study objectives are to evaluate the safety of the investigational product,
autologous EIE cells, to subjects by intravenous and intratumoral injections. The secondary
study objectives are (1) to evaluate the success rate of generating autologous EIE cells ex
vivo, and (2) to determine the anti-cancer efficacy of the EIE cells.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|